Literature DB >> 15448683

Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury.

Liqun Yu1, Zhihong Huang, Juliana Mariani, Yumei Wang, Michael Moskowitz, Jiang-Fan Chen.   

Abstract

Inactivation of the adenosine A(2A) receptor (A(2A)R) consistently protects against ischemic brain injury and other neural insults, but the relative contribution of A(2A)Rs on peripheral inflammatory cells versus A(2A)Rs expressed on neurons and glia is unknown. We created a chimeric mouse model in which A(2A)Rs on bone marrow-derived cells (BMDCs) were selectively inactivated or reconstituted by bone marrow transplantation. Selective reconstitution of A(2A)Rs on BMDCs (A(2A)R knockout mice transplanted with wild-type bone marrow cells) largely reinstates ischemic brain injury in global A(2A)R knockout mice. Conversely, selective inactivation of A(2A)Rs on BMDCs (wild-type mice transplanted with A(2A)R knockout bone marrow cells) attenuates infarct volumes and ischemia-induced expression of several proinflammatory cytokines in the brain, but exacerbates ischemic liver injury. These results indicate that the A(2A)R-stimulated cascade in BMDCs is an important modulator of ischemic brain injury and that ischemic brain and liver injuries are regulated distinctly by A(2A)Rs on BMDCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448683     DOI: 10.1038/nm1103

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  54 in total

1.  Inactivation of endothelial adenosine A2A receptors protects mice from cerebral ischaemia-induced brain injury.

Authors:  Yaqi Zhou; Xianqiu Zeng; Ge Li; Qiuhua Yang; Jiean Xu; Min Zhang; Xiaoxiao Mao; Yapeng Cao; Lina Wang; Yiming Xu; Yong Wang; Yu Zhang; Zhengshuang Xu; Chaodong Wu; Jiang-Fan Chen; Md Nasrul Hoda; Zhiping Liu; Mei Hong; Yuqing Huo
Journal:  Br J Pharmacol       Date:  2019-05-21       Impact factor: 8.739

Review 2.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 3.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

Review 4.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Continuous adenosine A2A receptor antagonism after focal cerebral ischemia in spontaneously hypertensive rats.

Authors:  Ulrike Fronz; Alexander Deten; Frank Baumann; Alexander Kranz; Sarah Weidlich; Wolfgang Härtig; Karen Nieber; Johannes Boltze; Daniel-Christoph Wagner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-10-30       Impact factor: 3.000

6.  2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine inhibit TNF-α and CXCL10 production from activated primary murine microglia via A2A receptors.

Authors:  Elizabeth A Newell; Jennifer L Exo; Jonathan D Verrier; Travis C Jackson; Delbert G Gillespie; Keri Janesko-Feldman; Patrick M Kochanek; Edwin K Jackson
Journal:  Brain Res       Date:  2014-11-03       Impact factor: 3.252

7.  AM-36 modulates the neutrophil inflammatory response and reduces breakdown of the blood brain barrier after endothelin-1 induced focal brain ischaemia.

Authors:  R M Weston; B Jarrott; Y Ishizuka; J K Callaway
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 8.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

9.  Adenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity.

Authors:  David Ribé; David Sawbridge; Sapna Thakur; Martin Hussey; Catherine Ledent; Ian Kitchen; Susanna Hourani; Jian-Mei Li
Journal:  Free Radic Biol Med       Date:  2008-01-05       Impact factor: 7.376

10.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.